scholarly journals Corrigendum to “Modulation of Short-Chain Fatty Acids as Potential Therapy Method for Type 2 Diabetes Mellitus”

Author(s):  
Ruiqi Tang ◽  
Lanjuan Li

Author(s):  
Ruiqi Tang ◽  
Lanjuan Li

In recent years, the relationship between intestinal microbiota (IM) and the pathogenesis of type 2 diabetes mellitus (T2DM) has attracted much attention. The beneficial effects of IM on the metabolic phenotype of the host are often considered to be mediated by short-chain fatty acids (SCFAs), mainly acetate, butyrate, and propionate, the small-molecule metabolites derived from microbial fermentation of indigestible carbohydrates. SCFAs not only have an essential role in intestinal health but might also enter the systemic circulation as signaling molecules affecting the host’s metabolism. In this review, we summarize the effects of SCFAs on glucose homeostasis and energy homeostasis and the mechanism through which SCFAs regulate the function of metabolically active organs (brain, liver, adipose tissue, skeletal muscle, and pancreas) and discuss the potential role of modulation of SCFAs as a therapeutic method for T2DM.


Author(s):  
Dominic Salamone ◽  
Angela Albarosa Rivellese ◽  
Claudia Vetrani

AbstractGut microbiota and its metabolites have been shown to influence multiple physiological mechanisms related to human health. Among microbial metabolites, short-chain fatty acids (SCFA) are modulators of different metabolic pathways. On the other hand, several studies suggested that diet might influence gut microbiota composition and activity thus modulating the risk of metabolic disease, i.e. obesity, insulin resistance and type 2 diabetes. Among dietary component, dietary fibre may play a pivotal role by virtue of its prebiotic effect on fibre-fermenting bacteria, that may increase SCFA production. The aim of this review was to summarize and discuss current knowledge on the impact of dietary fibre as modulator of the relationship between glucose metabolism and microbiota composition in humans. More specifically, we analysed evidence from observational studies and randomized nutritional intervention investigating the relationship between gut microbiota, short-chain fatty acids and glucose metabolism. The possible mechanisms behind this association were also discussed.


el–Hayah ◽  
2014 ◽  
Vol 5 (1) ◽  
pp. 9
Author(s):  
Nurlaili Susanti

<em>Diabetes is a group of metabolic diseases characterized by hyperglycemia. Type 2 Diabetes is most commonly type which accounts for 90-95% of those, resulting from defects in insulin secretion and insulin action. Management of type 2 diabetes should combine pharmacological therapy with both diet modification and increasing physical activity. Nutraceutical was known to have important role. A kind of Araceae family, Porang (Amorphophallus muelleri Blume), has a main content of glucomannan. Glucomannan is a water-soluble polysaccharide, high fibers and low calories. Various studies suggest the benefit effects of glucomannan in type 2 diabetes mellitus to improve blood glucose level and lipid profiles. Its mechanism is postulated to be associated with the intrinsic physical effects of soluble fiber in the gastrointestinal tract and fermentation by microflora in the large intestine that trigger production of several gut hormones. Short Chain Fatty Acids, product of fiber fermentation, can improve insulin sensitivity through competition with free fatty acids and increasing expression of GLUT 4 in insulin sensitive tissues. Therefore, glucomannan from Porang has a great potential to be a nutraceutical for the management of type 2 diabetes mellitus.</em>


2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Alessandra Puddu ◽  
Roberta Sanguineti ◽  
Fabrizio Montecucco ◽  
Giorgio Luciano Viviani

In type 2 diabetes, hyperglycemia, insulin resistance, increased inflammation, and oxidative stress were shown to be associated with the progressive deterioration of beta-cell function and mass. Short-chain fatty acids (SCFAs) are organic fatty acids produced in the distal gut by bacterial fermentation of macrofibrous material that might improve type 2 diabetes features. Their main beneficial activities were identified in the decrease of serum levels of glucose, insulin resistance as well as inflammation, and increase in protective Glucagon-like peptide-1 (GLP-1) secretion. In this review, we updated evidence on the effects of SCFAs potentially improving metabolic control in type 2 diabetes.


2010 ◽  
Vol 1 (4) ◽  
pp. 433-437 ◽  
Author(s):  
H. Roelofsen ◽  
M. Priebe ◽  
R. Vonk

Short chain fatty acids (SCFA) are the main bacterial metabolites of colonic fermentation processes. The physiological relevance of the SCFA for the host outside the gastrointestinal tract is getting increased attention. In this review we will focus on the effect of SCFA on inflammation processes in the host in relation to insulin resistance. Obesity has been associated with a pro-inflammatory state of the adipose tissue that is associated with whole body insulin resistance leading to type 2 diabetes. Recently, two G protein-coupled receptors (GPCR) for SCFA, GPCR 41 and GPCR43, were described that are mainly expressed by immune cells but also by adipose tissue. Propionate can induce the satiety hormone leptin and reduce expression of inflammatory cytokines and chemokines indicating that SCFA have anti-inflammatory effects in human adipose tissue. In addition, in human nutritional experiments we observed that whole grain products could counteract a glucose-induced tumour necrosis factor α and interleukin-6 increase which was associated with increased plasma butyrate concentrations. This suggests that dietary fibre can produce a SCFA profile that could have anti-inflammatory effects in the body. The physiological relevance of these observations especially in relation to obesity-associated inflammation and insulin resistance is discussed.


Sign in / Sign up

Export Citation Format

Share Document